Compare VCV & STTK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | VCV | STTK |
|---|---|---|
| Founded | N/A | 2016 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Trusts Except Educational Religious and Charitable | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 487.7M | 474.6M |
| IPO Year | 1994 | 2020 |
| Metric | VCV | STTK |
|---|---|---|
| Price | $9.19 | $4.45 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 12 |
| Target Price | N/A | ★ $15.40 |
| AVG Volume (30 Days) | 216.9K | ★ 925.0K |
| Earning Date | 01-01-0001 | 11-05-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 53.02 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $1,000,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $14.28 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $8.70 | $1.93 |
| 52 Week High | $11.38 | $8.33 |
| Indicator | VCV | STTK |
|---|---|---|
| Relative Strength Index (RSI) | 44.33 | 35.65 |
| Support Level | $8.78 | $4.38 |
| Resistance Level | $10.80 | $7.66 |
| Average True Range (ATR) | 0.15 | 0.38 |
| MACD | -0.03 | -0.02 |
| Stochastic Oscillator | 11.67 | 8.14 |
Invesco California Value Municipal Income Trust is a closed-end management investment company. Its investment objective is to provide common shareholders with a high level of current income, exempt from federal and California income taxes, consistent with the preservation of capital.
Shattuck Labs Inc is a biotechnology company specializing in the development of potential treatments for inflammatory and immune-mediated diseases. It is developing a potentially first-in-class antibody for the treatment of inflammatory bowel disease (IBD) and other inflammatory and immune-mediated diseases. The company's expertise in protein engineering and the development of novel tumor necrosis factor (TNF) receptor therapeutics comes together in its main program, SL-325, which has the potential to be a first-in-class death receptor 3 (DR3) antagonist antibody. In addition, the company is developing SL-425, a half-life extended version of SL-325, and multiple other preclinical DR3-based bispecific antibodies, for the treatment of patients with IBD.